Translational research in drug development: Bridging the gap between lab and clinic
Introduction: The translation problem in biomedical research
Clinical development remains a high-attrition stage for drug candidates. Across therapeutic areas, an estimated 80 to 90% of candidates entering human studies do not reach approval, despite having passed earlier scientific, technical, and investment filters. Analyses of clinical success rates also show that fewer than one in ten programmes entering Phase I ultimately gain approval, although success varies by therapeutic area and drug modality. Lack of efficacy, safety findings, and weak target or candidate rationale are recurring contributors to that loss. For translational research drug development, the central challenge is turning strong preclinical signals into evidence that can withstand the complexity of human disease. The gap between promising preclinical data and clinical success remains one of the most persistent challenges in drug development.
Translational research drug development requires more than a linear handoff from discovery to clinical teams. It depends on evidence that the target is relevant in human disease, the model system is fit for purpose, the biomarker strategy can support decision-making, and the assay package is designed around the clinical question. Clear definitions matter before those design choices can be judged.
What is translational research? Definition and scope
Findings from basic laboratory science only create clinical value when they are developed into interventions, diagnostics, procedures, or care pathways that improve human health. Translational research is the systematic work of turning those findings into clinically meaningful applications, while testing whether the biology observed in controlled experimental systems remains relevant in patients.
The term covers the work needed to move laboratory and preclinical findings toward clinical relevance. In drug development, translation typically includes target validation, candidate selection, pharmacology, safety planning, biomarker strategy, and early clinical study design. The aim is to design studies that test whether the biology observed in controlled experimental systems is likely to remain meaningful in patients.
For early-stage biotech and translational R&D teams, this early translational stage is usually the highest-risk zone. It is not simply a phase between discovery and the clinic. It is a way of designing experiments so that each result helps answer a future clinical question. The main risks become clearer when common failure modes are examined.
Why most preclinical findings fail to translate and the root causes
Preclinical to clinical translation often breaks down because the experimental evidence is answering a narrower question than the clinical program will face. A disease model may show a treatment effect, yet still fail to reflect the mechanisms, heterogeneity, comorbidities, and disease stage seen in patients. For example, in neurology, where neuroprotective agents repeatedly showed activity in rodent stroke models but failed in humans, partly because those models could not capture the vascular complexity, timing variability, inflammation, age, and clinical diversity of human stroke pathology.
Incomplete recapitulation of human disease by translational models is only one part of the challenge. Preclinical in vivo models typically make use of defined animal strains1, which can help control and regulate experimental testing. However, this approach can also underappreciate the genetic diversity that affects treatment response in patient populations.
Published data can add another layer of bias. Positive results are more likely to be reported than negative or null findings, which can make the supporting evidence look stronger than it really is2. For decision-makers, this creates a risk of overconfidence before the program has been tested against more representative biology. Study design can compound these issues. Use of single models, small sample sizes, weak randomization, and underpowered experiments can make effects look more convincing than they are. Endpoints may also capture only part of what is clinically meaningful, such as a short-term biomarker shift with limited predictive value for patient benefit. These failure modes are well documented and do not imply bad science. They reflect structural and methodological pressures that can be addressed through better translational design.
The principles of translationally-designed studies
1. Select models that reflect human disease mechanisms, not only operational convenience. Model choice should be driven by the biology of the intended indication, including pathway relevance, disease stage, immune context, tissue architecture, and known patient heterogeneity. Convenient or inexpensive models can still be useful, but they should not carry more decision weight than their biology supports. When model relevance is weak, apparent efficacy may reflect an artifact of the system rather than a signal likely to persist in patients.
2. Use clinically relevant biomarkers as endpoints wherever possible. Biomarkers should connect the preclinical experiment to pharmacology, target engagement, disease biology, or patient selection. Easy-to-measure surrogate markers can be misleading when they do not predict clinical response. In translational drug development, endpoint selection should clarify whether the candidate is acting on the intended mechanism and whether that mechanism is plausibly linked to patient benefit.
3. Use patient-derived material where it can answer a clear translational question. Primary cells, organoids, patient-derived xenografts, and ex vivo tissue can reveal disease biology that immortalized cell lines or animal models may miss3. They do not replace clinical evidence, and they come with practical limits around access, variability, and assay control. For translational medicine biotech programs, these models can bring human disease context into the work earlier, especially when response may depend on patient stratification, tissue specificity, or immune interactions.
4. Build reproducibility into the study design from the start. Studies need adequate sample sizes, pre-specified endpoints, randomization, blinding where feasible, and clear exclusion criteria. These controls reduce the chance that a weak or unstable result is treated as stronger evidence than it really is. Without these controls, a promising result may fail when repeated in another model, laboratory, or cohort. That can create false confidence before expensive development decisions are made.
5. Align preclinical endpoints with the intended clinical trial endpoints. Preclinical studies should anticipate the clinical question, not simply show that a candidate has activity. If the planned trial will measure functional improvement, lesion reduction, symptom change, or biomarker-defined response, the preclinical package should explain why earlier endpoints support that outcome.
6. Know the strengths and limitations of each translational model. No single model can fully predict human disease outcomes. A strong translational strategy depends on understanding what each model can and cannot tell you, then combining models in a way that makes the evidence more complete. Mouse models, clinically relevant biomarkers, patient-derived materials, clinical comparators, complex in vitro systems, and patient datasets can each answer different parts of the translational question. Used together, they can reduce the risk of relying too heavily on any one model and create a stronger basis for clinical decision-making.
Assay development is where many of these principles become operational.
Translational assay development: From cell lines to patient-derived models
In translational drug discovery assays, the goal is not simply to show that a candidate has activity, but to test whether that activity is relevant to human disease biology and future clinical decision-making. Translational assay development usually progresses from scalable systems toward models that retain more human disease biology. Established cell lines often provide the first layer of evidence. They are inexpensive, reproducible, highly adaptable, and compatible with high-throughput screening, which makes them useful for pathway interrogation, potency ranking, and early mechanism studies. Their challenge is that long-term culture can reshape genotype, phenotype, differentiation state, and drug response, leaving them distant from the tissue context seen in patients.
Primary cells add a more physiological view of target expression, pathway behavior, and cell-type-specific pharmacology. However, donor variability, limited availability, short culture windows, and sensitivity to handling can make them harder to standardize. Patient-derived organoids and co-culture systems add further complexity by preserving aspects of tissue architecture, cellular diversity, and intercellular signaling. They can be especially informative when epithelial, stromal, immune, or microenvironmental interactions influence response, although scalability, assay variability, and validation remain important constraints.
Ex vivo patient tissue sits closest to human biology, offering direct insight into pharmacology in diseased tissue. It is also scarce, technically demanding, and often unsuitable for large experimental matrices. Model selection should therefore follow the clinical question, not convenience or tradition4. That same logic applies to biomarker strategy, where the key issue is whether the measurement can support decisions in patients.
Translational biomarkers: Connecting biology to the clinic
Biomarkers give translational programs a way to connect mechanism, dose, patient biology, and clinical decision-making. Pharmacodynamic biomarkers show whether a candidate engages its target and modulates the intended pathway at relevant exposure levels. Predictive biomarkers serve a different purpose: they help identify the patient groups most likely to respond, based on target expression, pathway dependence, molecular subtype, immune profile, or another disease-linked feature.
These assays should be developed alongside efficacy assays, not added late as supporting evidence. When biomarker strategy is delayed until IND preparation, important questions about assay sensitivity, sample type, timing, dynamic range, and clinical feasibility may remain unresolved. Early biomarker development also supports better target confidence, especially when linked to human disease evidence and a clear rationale for patient selection.
Validated translational biomarkers can de-risk early clinical trials by confirming target engagement, informing dose selection, and supporting stratification before efficacy outcomes are mature. This is where integrated translational study design and specialist assay development become particularly valuable.
Translational research support at Discovery Studio
Discovery Studio’s translational track supports early-stage biotech and medtech programs that need to turn promising preclinical evidence into a credible and therapeutically relevant clinical positioning strategy. The work combines translational assay development, patient-derived model integration, and regulatory-aware study design, with senior scientific input throughout the program. Rather than applying an off-the-shelf package, each study plan is shaped around the therapeutic concept, disease biology, intended patient population, and evidence required for the next decision point. This includes designing proof-of-concept studies that generate decision-grade data and strengthening the rationale behind therapeutic hypotheses before major development commitments are made.
Search all newsposts
Popular Posts
Tags
Get in touch with us
Frequently asked questions about translational research in drug development
What is the difference between preclinical research and translational research?
Preclinical research tests biological hypotheses, candidate activity, safety signals, and mechanism in non-human systems. Translational research drug development asks whether those findings are likely to remain meaningful in patients, and whether the evidence package can support clinical decisions.
Why do so many drugs fail in translation from the lab to the clinic?
Failures often arise when preclinical evidence does not reflect human disease biology, patient heterogeneity, clinical endpoints, or feasible dosing. Preclinical to clinical translation is weakened further by underpowered studies, publication bias, limited model diversity, and endpoints that do not predict patient benefit.
What are translational biomarkers and why do they matter?
Translational biomarkers connect mechanism to clinical decision-making. Pharmacodynamic biomarkers show whether a candidate engages its target and changes the intended pathway. Predictive biomarkers help identify patients most likely to respond, supporting dose selection, patient stratification, and early evidence of biological activity.
At what stage of drug development does translational research begin?
Translational research should begin during early discovery, not after candidate nomination or IND preparation. Target selection, model choice, assay design, biomarker planning, and endpoint strategy all shape whether later preclinical findings can support a credible clinical rationale.
What is the difference between T1 and T2 translation?
T1 translation is the stage where findings from laboratory and preclinical research are carried forward into the first testing of an intervention in humans. T2 translation comes later, once there is evidence of clinical benefit. At this stage, the focus shifts to how the intervention can be adopted more widely, including implementation in routine care, improving access, developing care pathways, and evaluating effectiveness in real-world settings.
How can patient-derived models improve translational success rates?
Patient-derived models can preserve disease-relevant biology that simplified systems often miss, including genetic diversity, tissue architecture, pathway dependence, and micro environmental signaling. They do not remove translational risk, but they can make earlier evidence more clinically informative when selected and validated carefully.
References
- Brekke, T. D., Steele, K. A., & Mulley, J. F. Inbred or Outbred? Genetic Diversity in Laboratory Rodent Colonies. G3: Genes, Genomes, Genetics 8(2), 679–686 (2018). DOI: 10.1534/g3.117.300495.
- Sena, E. S., van der Worp, H. B., Bath, P. M. W., Howells, D. W., & Macleod, M. R. Publication Bias in Reports of Animal Stroke Studies Leads to Major Overstatement of Efficacy. PLoS Biology 8(3), e1000344 (2010). DOI: 10.1371/journal.pbio.1000344.
- Idrisova, K. F., Simon, H.-U., & Gomzikova, M. O. Role of Patient-Derived Models of Cancer in Translational Oncology. Cancers 15(1), 139 (2023). DOI: 10.3390/cancers15010139.
- Hughes, D. L., Hughes, A., Soonawalla, Z., & Mukherjee, S. Dynamic Physiological Culture of Ex Vivo Human Tissue: A Systematic Review. Cancers 13(12), 2870 (2021). DOI: 10.3390/cancers13122870.